Baiju Aurora started their work experience in 1999 as a Professional Product Representative at Roche. Baiju then moved on to work as a Senior Territory Manager at Allergan from 2000 to 2004. After that, they worked as a Retina Account Manager at OSI Eyetech from 2004 to 2007. From 2008 to 2011, they held the position of Senior Vice President of Business Development at Heron Evidence Development. Following that, they worked as the Senior Vice President of Global Commercial Development at Market Access Solutions LLC from 2011 to 2013. In 2013, Aurora became the President of Pricing, Market Access, and HEOR support to Pharma/Biotech at Aurora Capital LLC. Currently, they are serving as the Chief Executive Officer at Market Access Transformation since December 2015.
Baiju Aurora obtained a Bachelor of Science (BS) degree in Marketing from Rutgers University, graduating between the years 1995 and 1999. Subsequently, they pursued a Part-Time MBA in Marketing from Rutgers Business School, completing their studies from 2004 to 2009.
Market Access Transformation, a Genesis Research company
**May 2022 Genesis Research acquired Marketing Access Transformation** Founded in 2016, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange insights that asses the real-world potential of their pharmaceutical products. With close to 65 employees that span the US, UK and India, MAT is seen as a revolutionary company in the global pharmaceutical research space. Our primary platform, Rapid Payer Responses™ (RPR), enables pharmaceutical manufacturers to conduct critical market access research throughout the product and treatment development process. Through our global, vetted payer network, it is possible to gather more accurate, robust feedback and insights by probing further and asking deeper questions. you always have the exact answers you need in a fraction of the time and cost of a traditional payer research project. Our life science experts help facilitate this process, monitoring the responses in real time as they come in for quality and detail. Since the launch of Rapid Payer Response™ (RPR) in July 2016, we have partnered with over 50 of the leading pharmaceutical manufacturers, expanded our payer network to more than 45 countries and have achieved an impressive 93% license renewal rate as we continue to disrupt the older and outdated models for payer research. Were are diverse minded, global company with offices in the US (NJ, NY & CA), UK and India. If you are interested in joining our amazing MAT team, check our openings at https://www.marketaccesstransformation.com/careers